

BJA Education, 15 (4): 213-218 (2015)

doi: 10.1093/bjaceaccp/mku030 Advance Access Publication Date: 14 October 2014

Perioperative acute kidney injury

Jamie L Gross MBChB MRCP FRCA FFICM EDIC¹ and John R Prowle MA MSc MD MRCP DICM FFICM^{2,*}

¹ST7 Anaesthesia and ICM, Department of Anaesthesia and Intensive Care, Royal Free Hospital, Royal Free London NHS Foundation Trust, London, UK, and ²Consultant in Intensive Care and Renal Medicine, Adult Critical Care Unit and Department of Renal Medicine and Transplantation, The Royal London Hospital, Barts Health NHS Trust Whitechapel Road, London E1 1BB, UK

*To whom correspondence should be addressed. Tel: +44 20 359 40322/40346; Fax: +44 20 35940347; E-mail: john.prowle@bartshealth.nhs.uk

Key points

- Acute kidney injury (AKI) is a common problem in the perioperative period and an independent contributor to morbidity and mortality.
- Newer diagnostic criteria based on changes in serum creatinine and decreased urine output have improved earlier detection of AKI but are neither fully sensitive nor specific.
- Tubular injury results from a complex interaction between baseline pre-disposition, haemodynamic disturbances, nephrotoxic insults and inflammatory responses.
- Striking a careful balance between fluid under- and over-resuscitation, maintaining adequate systemic arterial pressure and avoidance of nephrotoxins are the cornerstones to preventing or halting the progression of kidney disease.
- Cardiopulmonary bypass and i.v. contrast are additional factors contributing to AKI in cardiac and endovascular surgery respectively.

Acute kidney injury (AKI) is a syndrome of abrupt decline in renal excretory and homeostatic function. This results in bloodstream accumulation of products of nitrogenous metabolism and failure to regulate body fluid volume, electrolyte concentrations and acid-base balance. Although the incidence of AKI varies according to the sensitivity of definition, some form of renal dysfunction can be observed in ~10% of all acute care hospitalizations¹

and more than <u>50%</u> of patients admitted to intensive care units (ICUs). In a large study of patients with normal renal function undergoing <u>non-cardiac</u> surgery, the incidence of AKI using sensitive modern definitions was <u>7.5%</u>.² AKI is both a sensitive marker of physiological distress and an independent contributor to morbidity and mortality and even mild transient renal dysfunction has been associated with increased risk of death^{1 2} and healthcare costs.¹ In addition, it is now recognized that in survivors, recovery from AKI is often incomplete and episodes of AKI are a significant risk factor to development or worsening of chronic kidney disease (CKD).³ Therefore, high-quality perioperative care should focus on evaluation of risk, early detection of AKI in order to improve patient outcomes.

Diagnosis of AKI

The term AKI has replaced the term 'acute renal failure' as it best describes a clinical spectrum of disease of differing severity rather than an all-or-none phenomenon of organ failure. This change has been accompanied by the realization that serum creatinine (SCr) has many limitations for the diagnosis of acute renal dysfunction. SCr is a product of muscle breakdown and therefore depends on age, gender, nutrition and muscle mass. Creatinine values thus have to be placed in the context of the individual patient and point in the time-course of AKI. At steady state, SCr is reciprocally related to glomerular filtration rate (GFR), but only starts to increase significantly when ~50% of glomerular filtration has been lost (Fig. 1). In addition, baseline SCr values will imply very different GFR depending on age, sex and race (Fig. 2). Therefore, it is possible that early renal dysfunction may often go undetected.

The development of the Risk, Injury, Failure, Loss, End Stage (RIFLE) classification of AKI in 2004 refocused approaches to

© The Author 2014. Published by Oxford University Press on behalf of the British Journal of Anaesthesia. All rights reserved. For Permissions, please email: journals.permissions@oup.com



Fig 1 Steady-state SCr plotted vs GFR in a 70-yr-old white male. Large changes in GFR can be associated with small changes in SCr in and just above the 'normal range'.



Fig 2 Predicted change in normal GFR and SCr with age in a white female. The same creatinine is associated with very different GFR at different ages. Creatinine generation and GFR decline in parallel with age.

AKI.⁴ These criteria have most recently been updated in the 2012 Kidney Disease Improving Global Outcomes (KDIGO) criteria for the diagnosis and management of AKI (Table 1).⁵ This diagnostic classification of AKI emphasizes relative increases in SCr from baseline as a more accurate marker of worsening glomerular function than actual SCr values alone. However, in the dynamic situation of individuals with acute illness, applying these definitions can be more difficult as there is often a time lag between an <mark>acute decrease in GFR and an increase in SCr</mark> to a new steady state, which itself may be further delayed by changes in volume of distribution and creatinine generation rate. In recognition of this, urine output criteria have been incorporated into

Stage	Serum Creatinine	Urine output
1	1.5–1.9 times baseline or $\geq 0.3 \text{ mg dl}^{-1}$ ($\geq 26.5 \mu \text{mol litre}^{-1}$) increase within 48 b	\leq 0.5 ml kg ⁻¹ h ⁻¹ for 6–12 h
2 3	2.0-2.9 times baseline 3.0 times baseline or Increase in serum creatinine to ≥4.0 mg dl ⁻¹ (≥353.6 µmol litre ⁻¹) or Initiation of renal replacement therapy or In patients <18 yr, decrease in eGFR to <35 ml min ⁻¹ per 1.73 m ²	≤0.5 ml kg ⁻¹ h ⁻¹ for 12 h ≤0.3 ml kg ⁻¹ h ⁻¹ for 24 h or Anuria for × 12 h

standardized AKI definitions. Sustained oliguria (>12 h) is a highly specific marker of AKI; however, it is insensitive as significant reduction in GFR can occur in the absence of oliguria. Conversely, shorter periods of low urine output are less specific in the perioperative situation as they may merely reflect response to physiological stress and transient haemodynamic changes in the <u>absence</u> of worsening kidney function.⁶

AKI pathophysiology

The aetiology of AKI is traditionally classified into pre-renal, intrinsic and post-renal causes (Table 2). However, while the identification of obstruction and intrinsic kidney diseases (such as interstitial nephritis) is important, these diagnoses comprise only a small proportion of cases of postoperative AKI, the majority of which is related to tubular injury of multifactorial aetiology. In true pre-renal AKI, haemodynamic compromise and neuroendocrine responses result in decreased GFR and oliguria that is fully reversible with correction of haemodynamic disturbances. In reality, there is usually significant overlap with tubular injury triggered by prolonged haemodynamic disturbance and so clinical efforts to distinguish pre-renal AKI from intrinsic tubular injury are rarely successful or helpful. The pathogenesis of tubular injury after major surgery is a result of complex interaction between baseline pre-disposition, haemodynamic disturbances, nephrotoxic insults and inflammatory responses. Inflammatory mechanisms play a central role, causing both direct cellular injury and inflammation-induced microcirculatory dysfunction contributing to local tissue ischaemia. Thus AKI is often one expression of the inflammatory processes that underlies general multi-organ dysfunction in critical illness. Tissue ischaemia is likely to play an important role in the initiation of perioperative AKI; however, renal injury may persist because of ischaemiainduced inflammation and local alterations in microvascular perfusion. Pre-glomerular resistance may in turn be increased in response to tubular injury, reducing renal perfusion that is independent of systemic haemodynamics. Thus, once established, these processes may not be readily reversed by manipulation of the systemic circulation aimed at maximizing global renal oxygen delivery. Recognition of stage in the pathophysiology of AKI is therefore essential in selecting appropriate likely clinical progress and appropriate management (Fig. 3).

Table 2 Aetiological classification of AKI

Haemodynamic 'Pre-renal'	Intrinsic renal disease	Post-renal
Hypovolaemia	Acute tubular injury	Obstruction
Bleeding	Multifactorial aetiology with common	Prostatic hypertrophy, nephrolithiasis, retroperitoneal
Dehydration	inflammatory pathogenesis	fibrosis, pelvic masses, bladder tumours, etc.
Extravasation	Causes	
Vasodilatory hypotension	Systemic inflammation	
Sepsis	Sepsis, major surgery, CPB, etc.	
Low cardiac output states	Prolonged or total ischaemia	
Acute and chronic heart failure	Unresolved haemodynamic factors	
	Exogenous nephrotoxins	
	Aminoglycosides, radiological	
	contrast, etc.	
	Pigment nephropathy	
	Rhabdomyolysis,	
	haemolysis including cardiopulmonary	
	bypass	
Locally impaired renal circulation	Metabolic syndromes	
Medication (ACEI, A2RB, NSAIDs)	Hypercalcaemia, hyperuricaemia	
Renovascular disease	Autoimmune/inflammatory	
CKD	Glomerulonephritis	
Chronic liver disease	Vasculitis	
Abdominal compartment syndrome	Thromobotic microangiopathies	
	Interstitial nephritis	

ACEI, angiotensin converting enzyme inhibitor; A2RB, angiotensin II receptor blocker; NSAID, non-steroidal anti-inflammatory; CKD, chronic kidney disease.

Preoperative: assessment and planning

Preoperative assessment should aim to identify those at greatest risk of AKI, allowing pre-optimization and planning for higher level postoperative care and monitoring in the most vulnerable. Risk factors can be divided into patient, operative, and pharmacological factors (Table 3). Although many patient risk factors are unmodifiable, efforts should be made to optimize cardiorespiratory status, nutrition and glycaemic control and to minimize nephrotoxin exposure. Cardiopulmonary exercise testing can be used to better define cardiorespiratory reserve to aid risk stratification. Those with known CKD are at highest risk for AKI and require most careful attention to arterial pressure and fluid balance. The need for nephrotoxic medication, such as non-steroidal anti-inflammatories, should be balanced against risk of AKI and such medication should be avoided in patients with significant risk factors. Antibiotics with nephrotoxic properties, such as aminoglycosides, should be judiciously considered, taking into account the degree and likelihood of microbial contamination or active infection and likely sensitivities to the antibiotics in question. Sepsis is the leading cause of AKI in the ICU and concerns about nephrotoxicity should not prevent adequate treatment of infection, providing dosing and monitoring for level of renal function is appropriate. The need for regular antihypertensive medication in the perioperative period should also be reviewed considering the likelihood of postoperative vasodilatory hypotension and additional risk factors such as epidural anaesthesia. In particular, angiotensin-converting enzyme inhibitors and angiotensin-II receptor blockers will selectively reduce glomerular perfusion pressure and systemic arterial pressure. Although clinical trials showing a clear benefit of omission of these agents during the perioperative phase are lacking, it is suggested that for high-risk patients and those with limited cardiovascular reserve, they should not be given on the day of surgery and not recommenced until after recovery from the acute effects of surgery.

Perioperative management

Haemodynamic management and fluid therapy

Targeted approaches to perioperative haemodynamic management have been shown to improve patient and renal outcomes after high-risk surgery and we suggest that goal-directed perioperative fluid management should be considered in patients deemed at high risk of AKI and all patients undergoing highrisk surgery. Such goal-directed therapy (GDT) strategies involve titrating fluid boluses and/or inotropic drugs to endpoints such as cardiac output (as provided by oesophageal Doppler, pulse contour waveform analysis, or dilutional techniques) or markers of end organ perfusion (such as arterial lactate). Adequate monitoring of fluid resuscitation is essential in at-risk patients as there is often a fine balance to be met between resuscitating to achieve an adequate cardiac output (to prevent renal ischaemia) and avoidance of fluid overload, which is associated with adverse postoperative outcomes. Several lines of evidence suggest that fluid overload may worsen AKI,7 decrease survival in those developing AKI and is associated with impaired recovery of renal function in patients surviving critical illness.⁸ Timing of fluid resuscitation may also be crucial and experimental evidence suggests that early compared with late systemic resuscitation in systemic inflammatory states reduces renal inflammation and improves microvascular perfusion.9 Therefore, GDT protocols may afford the best method of minimizing risk of hypovolaemia, delayed resuscitation, and fluid overload. A recent metaanalysis not only demonstrated a reduction in AKI with the use of perioperative GDT, but also showed that overall, the amount of fluid given in the GDT group was similar to the non-GDT group.¹⁰ This suggests that the <mark>timing</mark> and appropriate targeting of fluid therapy is the important factor and is unlikely to contribute to fluid overloaded states.

Composition of resuscitation fluid remains an area of controversy. Evidence of increased harm with starches and lack of



Fig 3 Clinical course of AKI. Initiation of AKI can involve haemodynamic changes in GFR, subclinical tubular injury or both processes occurring simultaneously. A short window may exist where specific therapy might reverse AKI; however, this treatment may need to be tailored to the nature of the injury. Established AKI requires days to weeks for recovery, emphasis here should be on supportive therapy and the avoidance of secondary renal injury that may result in non-recovery of renal function or CKD. [Reproduced with permission from Prowle JR. Acute kidney injury: an intensivist's perspective. *Pediatr Nephrol* (2014; 29: 13–21).].

Table 3 Risk factors for perioperative AKI

Patient	Operative	Pharmacological
Age	Emergency surgery	Non-steroidal anti-inflammatory agents
Male sex	Cardiac surgery	Angiotensin-converting enzyme inhibitors or angiotensin-II receptor blockers
CKD	Liver transplant surgery	Antibiotics (aminoglycosides, glycopeptides, etc.)
Chronic cardiac failure	Vascular surgery	Immunosuppressive drugs (calcineurin inhibitors)
Hypertension	Intraperitoneal surgery	Hydroxyethylstarch solutions
Chronic liver disease	Duration of surgery	Radiological contrast
Diabetes mellitus	Major haemorrhage	-
Sepsis	Blood transfusion	
Limited cardiorespiratory reserve	Intraoperative hypovolaemia and hypotension	

clear benefit compared with crystalloids or albumin led to its withdrawal in June 2013. However, there is currently no clear consensus on superiority between albumin and crystalloids. For crystalloids, there is evidence that balanced salt solutions should be given in preference to 0.9% saline, which has been associated with development of hyperchloraemic acidosis, decreased renal blood flow (RBF), and increase risk of AKI.¹¹

Vasopressors

Maintaining an adequate mean arterial pressure (MAP) is essential to preserving renal function, both to ensure adequate renal perfusion pressure and to maintain the transglomerular pressure gradient for ultrafiltration. Hypotension related to systemic vasodilation, as a consequence of systemic inflammatory response to surgical trauma or sepsis, or the effects of medication and neuroaxial block is common in postoperative settings. Vasodilatory hypotension is unlikely to respond to fluid therapy and over-reliance on i.v. fluids in these settings is likely to lead to prolonged hypotension and fluid overload. While vasoconstrictors have historically been regarded as potentially harmful to an ischaemic kidney, most available evidence favours moderate vasopressor use in vasodilatory shock. The use of norepinephrine has been shown to improve RBF, GFR, and urine output in experimental models of septic-AKI and clinical settings. This is because systemic vasoconstrictors have a larger positive effect in increasing renal perfusion pressure than a negative effect caused by increases in renal vascular resistance. Vasopressor management in AKI requires consideration of what MAP is normal for any individual and higher levels may need to be targeted in the elderly and chronically hypertensive. It is difficult to make specific recommendations; however, increasing MAP up to 75 mm Hg has been shown to increase renal oxygen delivery and GFR during post-cardiac surgery AKI, while higher targets did compromise renal perfusion in some.¹²

Other specific therapies

There is no evidence that renal vasodilators prevent the onset or halt the progression of AKI in clinical settings. In particular, a large randomized multicentre trial demonstrated that low-dose dopamine is ineffective in the treatment of early AKI.¹³ Such agents are not recommended outside clinical trial settings.

The use of diuretics should be limited to controlling fluid balance and preventing fluid overload. Although diuretics may improve urine output, there is no evidence that they reduce the onset of AKI or alter GFR. Inappropriate diuretic use risks hypovolaemia and additional renal injury.

There is also insufficient evidence to support the use of atrial natriuretic peptide, nesiritide (recombinant human β -natriuretic peptide) or theophylline in the prevention or treatment of AKI.

AKI in specific perioperative settings

Cardiac surgery

Up to 50% of high-risk patients undergoing cardiac surgery with cardiopulmonary bypass (CPB) develop some degree of postoperative AKI. Cardiac surgery-associated AKI involves several synergistically injury pathways including ischaemia-reperfusion injury, exogenous and endogenous toxins, inflammation, oxidative stress and vasodilation. The use of a CPB pump has been associated with elevation in levels of systemic inflammatory mediators and length of time on CPB is a well-recognized risk factor for the development of AKI. Oxido-inflammatory changes during CPB can be further exacerbated by haemolysis in the extra-corporeal circuit with release of free haemoglobin into the circulation. Haem-induced oxidant injury is likely to be a consequence of lipid peroxidation leading to the formation of potent renal vasoconstrictors and by direct cellular injury. Thus, in common with most forms of AKI, cardiac surgeryassociated AKI is multifactorial and management involves recognition of risk, early diagnosis, and supportive haemodynamic therapy. However, there are specific nephrotoxic features of CPB and some evidence suggests that 'off-pump' surgery, where feasible, is associated with lower risk of AKI.14

Endovascular surgery

Interventional procedures such as endovascular aortic repair are associated with specific risk of AKI. Mechanism of renal injury is again multifactorial with mechanisms including contrastinduced AKI (CI AKI), guidewire embolization of atheromatous material from major vessels, perioperative hypotension, and inflammation. CI AKI can occur in as many as 25% of patients with pre-existing renal impairment or those exposed to other major risk factors. Postulated mechanisms of contrast toxicity include increased systemic vasoconstriction, decreased local prostaglandin and nitric oxide-mediated vasodilatation and a direct toxic effect on renal tubular cells. Current consensus recommendations are to use the lowest possible dose of iso- or hypo-osmolar contrast. In order to limit the cumulative dose of contrast at the time of surgery, preparative imaging should be done as far in advance as possible. Avoidance of hypovolaemia and adequate hydration with isotonic crystalloid has been proven to reduce the risk of CI AKI. While sodium bicarbonate has theoretical benefits over isotonic saline, evidence of clinical superiority is lacking. A suggested fluid regime is <u>3 ml kg⁻¹ of isotonic crystalloid (0.9%</u> saline, buffered solutions, or isotonic sodium bicarbonate) 1 h before exposure followed by 1 ml kg⁻¹ h⁻¹ post-exposure for 6-24 h. Prophylactic fluid therapy remains the only proven intervention for the prevention of CI AKI and there is currently insufficient evidence to recommend the use of theophylline, fenoldopam, or prophylactic haemodialysis or haemofiltration. Evidence for the use of N-acetylcysteine for the prevention of CI AKI is neither consistent nor overwhelming and recent guidelines produced by NICE¹⁵ and The UK Renal Association, British Cardiovascular Intervention Society and The Royal College of Radiologists¹⁶ suggest that there is no convincing benefit for prescribing oral or i.v. acetylcysteine or any other pharmacological agents to prevent CI AKI.

Conclusions

AKI is associated with significant perioperative morbidity and mortality but is complex to diagnose and lacks evidence-based clinical interventions. Preventive management relies on identification of patients at risk, avoidance of nephrotoxins, optimization of haemodynamics (including use of GDT) and assiduous monitoring during the period of risk. Current investigations for AKI have significant limitations and diagnosis is often late and imprecise. Once AKI is overt, the immediate clinical course may be unalterable and emphasis should be placed on best supportive care and avoidance of harm, including iatrogenic fluid overload, while recovery occurs.

Declaration of interest

None declared.

MCQs

The associated MCQs (to support CME/CPD activity) can be accessed at www.access.oxfordjournals.org by subscribers to BJA Education.

Podcasts

This article has an associated podcast which can be accessed at http://www.oxfordjournals.org/podcasts/ceaccp_15.04.01.mp3.

References

 Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005; 16: 3365–70

- 2. Abelha FJ, Botelho M, Fernandes V, Barros H. Determinants of postoperative acute kidney injury. Crit Care 2009; **13**: R79
- Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and metaanalysis. Kidney Int 2012; 81: 442–8
- Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8: R204–12
- Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO Clinical Practice Guideline for Acute Kidney Injury. Section 2: AKI definition. Kidney Int Suppl 2012; 2: 19–36
- Prowle JR, Liu YL, Licari E et al. Oliguria as predictive biomarker of acute kidney injury in critically ill patients. Crit Care 2011; 15: R172
- Prowle JR, Echeverri JE, Ligabo EV, Ronco C, Bellomo R. Fluid balance and acute kidney injury. Nat Rev Nephrol 2010; 6: 107–15
- Heung M, Wolfgram DF, Kommareddi M, Hu Y, Song PX, Ojo AO. Fluid overload at initiation of renal replacement therapy is associated with lack of renal recovery in patients with acute kidney injury. Nephrol Dial Transplant 2012; 27: 956–61
- 9. Legrand M, Bezemer R, Kandil A, Demirci C, Payen D, Ince C. The role of renal hypoperfusion in development of renal microcirculatory dysfunction in endotoxemic rats. *Intensive Care Med* 2011; **37**: 1534–42

- Prowle JR, Chua HR, Bagshaw SM, Bellomo R. Clinical review: volume of fluid resuscitation and the incidence of acute kidney injury: a systematic review. Crit Care 2012; 16: 230
- Yunos NM, Bellomo R, Hegarty C, Story D, Ho L, Bailey M. Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. J Am Med Assoc 2012; 308: 1566–72
- Redfors B, Bragadottir G, Sellgren J, Sward K, Ricksten SE. Effects of norepinephrine on renal perfusion, filtration and oxygenation in vasodilatory shock and acute kidney injury. Intensive Care Med 2011; 37: 60–7
- Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J. Lowdose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000; 356: 2139–43
- Lamy A, Devereaux PJ, Prabhakaran D et al. Off-pump or onpump coronary-artery bypass grafting at 30 days. N Engl J Med 2012; 366: 1489–97
- NICE Clinical Guideline 169 (issued August 2013). Acute Kidney Injury. Prevention, detection and management of acute kidney injury up to the point of renal replacement therapy. Available from http://guidance.nice.org.uk/cg169 (accessed 17 March 2014)
- http://www.rcr.ac.uk/docs/radiology/pdf/2013_RA_BCIS_RCR. pdf (accessed 17 March 2014)